Stryker Corporation (NYSE:SYK) insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $160.53, for a total value of $479,021.52. Following the sale, the insider now owns 9,100 shares in the company, valued at approximately $1,460,823. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Stryker Corporation (NYSE:SYK) traded down $0.26 during trading on Tuesday, reaching $154.14. The company had a trading volume of 2,728,936 shares, compared to its average volume of 1,471,085. Stryker Corporation has a 52-week low of $122.01 and a 52-week high of $170.00. The firm has a market capitalization of $57,680.00, a PE ratio of 57.51, a P/E/G ratio of 2.33 and a beta of 0.70. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.
Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.55% and a net margin of 8.20%. The firm had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the firm earned $1.78 earnings per share. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. analysts predict that Stryker Corporation will post 7.12 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. BT Investment Management Ltd purchased a new position in Stryker in the second quarter valued at about $237,000. Stevens Capital Management LP purchased a new position in Stryker in the second quarter valued at about $1,575,000. Choate Investment Advisors raised its position in Stryker by 5.6% in the second quarter. Choate Investment Advisors now owns 10,958 shares of the medical technology company’s stock valued at $1,521,000 after purchasing an additional 585 shares during the period. Profund Advisors LLC raised its position in Stryker by 8.1% in the second quarter. Profund Advisors LLC now owns 13,697 shares of the medical technology company’s stock valued at $1,901,000 after purchasing an additional 1,031 shares during the period. Finally, Thrivent Financial For Lutherans raised its position in Stryker by 5.0% in the second quarter. Thrivent Financial For Lutherans now owns 15,585 shares of the medical technology company’s stock valued at $2,169,000 after purchasing an additional 745 shares during the period. Hedge funds and other institutional investors own 74.85% of the company’s stock.
Several equities research analysts have recently issued reports on the company. Oppenheimer restated a “hold” rating and set a $165.00 price objective on shares of Stryker in a report on Thursday, February 1st. Citigroup restated a “market perform” rating and set a $165.00 price objective (up previously from $156.00) on shares of Stryker in a report on Thursday, February 1st. They noted that the move was a valuation call. Guggenheim restated a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Piper Jaffray Companies restated a “buy” rating and set a $170.00 price objective on shares of Stryker in a report on Wednesday, January 31st. Finally, Cantor Fitzgerald restated a “hold” rating and set a $163.00 price objective on shares of Stryker in a report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $162.50.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.